Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab

Per Soelberg Sørensen, Poul Erik Hyldgaard Jensen, Aiden Haghikia, Malin Lundkvist, Christian Vedeler, Finn Sellebjerg, Nils Koch-Henriksen, Anna Fogdell-Hahn, Kjell-Morten Myhr, Jan Hillert, Ralf Gold

52 Citations (Scopus)

Abstract

In the clinical trials about 9% of natalizumab treated multiple sclerosis (MS) patients generated anti-natalizumab antibodies, of which 6% were persistent and 3% transient. The occurrence of antibodies reduced serum levels of natalizumab, decreased bio-efficacy, and abrogated the therapeutic efficacy.
Original languageEnglish
JournalMultiple Sclerosis
Volume17
Issue number9
Pages (from-to)1074-8
Number of pages5
ISSN1352-4585
DOIs
Publication statusPublished - 2011

Keywords

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal, Humanized
  • Female
  • Humans
  • Integrin alpha4
  • Male
  • Middle Aged
  • Multiple Sclerosis, Relapsing-Remitting

Fingerprint

Dive into the research topics of 'Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab'. Together they form a unique fingerprint.

Cite this